Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma

Inclusion Criteria:

* Patients must have relapsed or primary refractory lymphoid malignancy (including B-cell, T-cell, or Hodgkin lymphoma), or multiple myeloma; other transplant eligible diagnoses (e.g. germ cell tumor) can be included with principal investigator (PI) approval
* World Health Organization (WHO) classification of patients' malignancies must be provided
* Patients with lymphoid malignancies must have a computed tomography (CT) of chest, abdomen, and pelvis within six weeks of enrollment; patients with evidence of lymphadenopathy in the neck must have a CT of neck
* Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Absolute neutrophil count (ANC) \>= 1,500/mm\^3
* Platelets \>= 100,000/mm\^3 (without transfusion or growth factor support)
* Creatinine clearance (CrCl) greater than 50/ml per minute (all tests must be performed within 28 days prior to registration)
* Total bilirubin \< 1.5 times upper limit of normal
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 2.5 times upper limit of normal
* All patients must be informed of the investigational nature of this study and have given written consent in accordance with institutional and federal guidelines
* Adequate venous access plan in place for apheresis procedure
* Three or fewer prior myelotoxic treatment regimens (specific regimens include ifosfamide, carboplatin and etoposide \[ICE\]; cisplatin, cytarabine, and dexamethasone \[DHAP\]; methotrexate \[MTX\]/high-dose cytarabine \[HiDAC\]; cyclophosphamide, vincristine, doxorubicin, and dexamethasone \[hyperCVAD\]; bortezomib, thalidomide, dexamethasone and 4-day continuous infusions of cisplatin, doxorubicin, cyclophosphamide, and etoposide \[VTD-PACE\])

Exclusion Criteria:

* Patients known positive for human immunodeficiency virus (HIV), or infectious hepatitis type B or C
* Pregnant or nursing women; men or women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method
* Greater than six prior cycles of lenalidomide therapy
* Patients who have previously demonstrated resistance to bendamustine therapy (i.e. no response or progression w/in 6 months)
* Fludarabine or other nucleoside analog (except gemcitabine or cytarabine) therapy within 24 months of registration; patients with limited exposure to fludarabine/other nucleoside analog therapy within 24 months may be considered eligible with review and approval by the PI or Co-PI prior to study entry
* Symptomatic cardiopulmonary disease
* Prior autologous or allogeneic transplantation
* Prior radioimmunotherapy within 12 weeks of registration
* Prior failed (\< 5 x 10\^6 CD34/kg) PBSC collection due to inability to mobilize stem cells
* Prior pelvic or spinal irradiation
* Previous systemic chemotherapy/immunotherapy within 3 weeks before study entry
* Concurrent use of other anti-cancer agents or experimental treatments
* Known allergy or intolerance to bendamustine, mannitol, GCSF or dexamethasone
* More than 3 cycles of myelotoxic salvage chemotherapy within the past 4 months (specific regimens include ICE, DHAP, MTX/HiDAC, hyperCVAD, VTD-PACE)